EHR Implementation Best Practices 

Get on track toward effectively implementing the CDC adult hepatitis B vaccination policy by leveraging tips and experience from trusted experts. 

Universal Adult Hepatitis B Vaccination Planner to guide the effective implementation of the CDC policy in your system.
Download this guide to plan the effective implementation of the CDC policy in your system.
Universal Adult Hepatitis B Vaccination Planner Click to download
Webinar discussing a population health approach to implementing universal hepatitis B vaccination in adults.
This webinar discusses a population health approach to implementing universal hepatitis B vaccination in adults.
WEBINAR: A Population Health Approach to Effectively Implementing Universal Hepatitis B Vaccination in Adults Click to watch video
Video clip discussing how implementing health information technologies can increase adult hepatitis B vaccination rates.
This video clip summarizes how institutions can successfully implement health information technologies to increase hepatitis B vaccination rates.
VIDEO CLIP: A Population Health Approach to Effectively Implementing Universal Hepatitis B Vaccination in Adults Click to watch video

CDC, Centers for Disease Control and Prevention; EHR, electronic health record. 

Important Safety Information

INDICATION

HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. 

IMPORTANT SAFETY INFORMATION

Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast. 

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B. 

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B. 

Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration. 

The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%). 

Please see full Prescribing Information.